Clinical trial data provide “a complex and conflicting picture” about the influence of treatment with disease-modifying drugs (DMDs) on relapse rates in women with multiple sclerosis (MS) who are pregnant or breastfeeding, researchers have reported.
Clinical trial data provide “a complex and conflicting picture” about the influence of treatment with disease-modifying drugs (DMDs) on relapse rates in women with multiple sclerosis (MS) who are pregnant or breastfeeding, researchers have reported.